S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
Elon Musk Sees Serious Crisis (Ad)
This Is Why Daktronics Fell 40% In One Day 
On the money: Yellen's next milestone is name on US currency
Elon Musk Sees Serious Crisis (Ad)
Biden releasing nearly $36B to aid pensions of union workers
Is It Time To Throw In The Towel On Gamestop?
The Critical Minerals Race: U.S. v China (Ad)
Closing prices for crude oil, gold and other commodities
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
Elon Musk Sees Serious Crisis (Ad)
This Is Why Daktronics Fell 40% In One Day 
On the money: Yellen's next milestone is name on US currency
Elon Musk Sees Serious Crisis (Ad)
Biden releasing nearly $36B to aid pensions of union workers
Is It Time To Throw In The Towel On Gamestop?
The Critical Minerals Race: U.S. v China (Ad)
Closing prices for crude oil, gold and other commodities
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
Elon Musk Sees Serious Crisis (Ad)
This Is Why Daktronics Fell 40% In One Day 
On the money: Yellen's next milestone is name on US currency
Elon Musk Sees Serious Crisis (Ad)
Biden releasing nearly $36B to aid pensions of union workers
Is It Time To Throw In The Towel On Gamestop?
The Critical Minerals Race: U.S. v China (Ad)
Closing prices for crude oil, gold and other commodities
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
Elon Musk Sees Serious Crisis (Ad)
This Is Why Daktronics Fell 40% In One Day 
On the money: Yellen's next milestone is name on US currency
Elon Musk Sees Serious Crisis (Ad)
Biden releasing nearly $36B to aid pensions of union workers
Is It Time To Throw In The Towel On Gamestop?
The Critical Minerals Race: U.S. v China (Ad)
Closing prices for crude oil, gold and other commodities
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
NASDAQ:NVIV

InVivo Therapeutics - NVIV Stock Forecast, Price & News

$1.82
-0.02 (-1.09%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.72
▼
$1.83
50-Day Range
$1.82
▼
$7.98
52-Week Range
$1.70
▼
$16.00
Volume
22,051 shs
Average Volume
113,889 shs
Market Capitalization
$3.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NVIV stock logo

About InVivo Therapeutics (NASDAQ:NVIV) Stock

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

Receive NVIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InVivo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NVIV Stock News Headlines

October 11, 2022 | finance.yahoo.com
InVivo Therapeutics Announces Closing of $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules
October 10, 2022 | marketwatch.com
InVivo Therapeutics Shares Continue Friday's Fall, Hit All-Time Intraday Low
October 7, 2022 | seekingalpha.com
InVivo Therapeutics dips 24% on $9M direct and private placement offerings
October 7, 2022 | marketwatch.com
InVivo Therapeutics Stock Drops on $9 Million Offering
October 7, 2022 | investorplace.com
Why Is InVivo Therapeutics (NVIV) Stock Down 34% Today?
October 7, 2022 | finance.yahoo.com
InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules
September 9, 2022 | finance.yahoo.com
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright 24th Annual Global Investment Conference
August 28, 2022 | uk.finance.yahoo.com
InVivo Therapeutics Holdings Corp. (NVIV)
July 13, 2022 | finance.yahoo.com
InVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General Counsel
June 8, 2022 | finance.yahoo.com
InVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed Neurosurgery
June 2, 2022 | finance.yahoo.com
InVivo Therapeutics Announces Completion of Enrollment for the INSPIRE 2.0 Acute Spinal Cord Injury Study
April 18, 2022 | finance.yahoo.com
Why Are InVivo Therapeutics Shares Trading Lower During Premarket Monday?
April 15, 2022 | nasdaq.com
Why InVivo Therapeutics Stock Falling?
April 14, 2022 | marketwatch.com
InVivo Therapeutics Announces 1-for-25 Reverse Stock Split
April 14, 2022 | finance.yahoo.com
InVivo Therapeutics stock sinks after 1-for-25 reverse stock split announced
April 14, 2022 | seekingalpha.com
InVivo Therapeutics slumps 7% on 1-for-25 reverse stock split
February 8, 2022 | finanznachrichten.de
Sidekick Health: DTx leader Sidekick announces key C-level hires in move to accelerate U.S. market growth
February 8, 2022 | finance.yahoo.com
DTx leader Sidekick announces key C-level hires in move to accelerate U.S. market growth
January 30, 2022 | fool.com
InVivo Therapeutics Holdings(NVIV)
January 6, 2022 | finance.yahoo.com
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright BioConnect Conference
December 29, 2021 | nasdaq.com
InVivo Therapeutics Holdings Corp Shares Fall 1.4% Below Previous 52-Week Low - Market Mover
December 29, 2021 | nasdaq.com
InVivo Therapeutics Holdings Corp Shares Close the Day 11.0% Lower - Daily Wrap
September 9, 2021 | finance.yahoo.com
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright Annual Global Investment Conference
September 8, 2021 | finance.yahoo.com
InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury Study
August 7, 2021 | nasdaq.com
InVivo Therapeutics Holdings Corp Common Stock (NVIV)
See More Headlines
Receive NVIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InVivo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NVIV Company Calendar

Last Earnings
5/13/2020
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/06/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVIV
CUSIP
N/A
CIK
1292519
Web
www.invivotherapeutics.com
Phone
(617) 863-5500
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($8.14)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-9,900,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-78.11%
Return on Assets
-63.33%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.62
Quick Ratio
4.62

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$13.22 per share
Price / Book
0.14

Miscellaneous

Outstanding Shares
1,910,000
Free Float
1,903,000
Market Cap
$3.48 million
Optionable
Not Optionable
Beta
0.89

Key Executives

  • Dr. Richard M. Toselli (Age 64)
    Pres, CEO, Chief Medical Officer & Director
    Comp: $940.27k
  • Mr. Richard C. Christopher (Age 52)
    CFO & Treasurer
    Comp: $628.2k
  • Dr. Robert S. Langer Jr. (Age 73)
    Ph.D., Sc.D., SCD, Co-Founder & Member of Scientific Advisory Board
  • Dr. Joseph Philip Vacanti (Age 73)
    Co-Founder
  • Mr. Jerome Gangitano
    Sr. VP of Operations
  • Ms. Heather M. Hamel J.D.
    Chief Legal Officer & Gen. Counsel
  • Dr. Louis Vaickus FACP (Age 69)
    M.D., Consultant

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













NVIV Stock - Frequently Asked Questions

How have NVIV shares performed in 2022?

InVivo Therapeutics' stock was trading at $11.4025 on January 1st, 2022. Since then, NVIV stock has decreased by 84.0% and is now trading at $1.82.
View the best growth stocks for 2022 here.

When is InVivo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023.
View our NVIV earnings forecast.

How were InVivo Therapeutics' earnings last quarter?

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) posted its quarterly earnings results on Wednesday, May, 13th. The biotechnology company reported ($61.75) earnings per share for the quarter.

When did InVivo Therapeutics' stock split?

InVivo Therapeutics shares reverse split on the morning of Wednesday, April 27th 2022. The 1-25 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of InVivo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InVivo Therapeutics investors own include Anavex Life Sciences (AVXL), Gilead Sciences (GILD), iShares Preferred and Income Securities ETF (PFF), Verastem (VSTM), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), Apollo Investment (AINV), IVERIC bio (OPHT), OPKO Health (OPK) and Cardiff Oncology (TROV).

What is InVivo Therapeutics' stock symbol?

InVivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."

Who are InVivo Therapeutics' major shareholders?

InVivo Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (2.24%), Renaissance Technologies LLC (1.45%), Vanguard Group Inc. (0.88%), Two Sigma Investments LP (0.60%) and Two Sigma Advisers LP (0.55%).
View institutional ownership trends.

How do I buy shares of InVivo Therapeutics?

Shares of NVIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InVivo Therapeutics' stock price today?

One share of NVIV stock can currently be purchased for approximately $1.82.

How much money does InVivo Therapeutics make?

InVivo Therapeutics (NASDAQ:NVIV) has a market capitalization of $3.49 million. The biotechnology company earns $-9,900,000.00 in net income (profit) each year or ($8.14) on an earnings per share basis.

How can I contact InVivo Therapeutics?

InVivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The official website for the company is www.invivotherapeutics.com. The biotechnology company can be reached via phone at (617) 863-5500 or via email at info@invivotherapeutics.com.

This page (NASDAQ:NVIV) was last updated on 12/9/2022 by MarketBeat.com Staff